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Background: This study presents the short-term and midterm results of direct percutaneous sac injection (DPSI) for
postoperative endoleak treatment after endovascular aortic aneurysm repair (EVAR).
Methods: Between March 1994 and November 2011, EVAR was performed in 986 patients. The median follow-up was 63
45 months (range, 0-211 months). A retrospective analysis was performed. DPSI was used in 21 patients for 19 type II
endoleaks and two endoleaks of undefined origin (EOUO), of which 12 (57%) were after failure of a previous
endovascular treatment attempt.
Results: DPSI using thrombin (n 16), coils (n 7), gelfoam (n 6), or glue (n 3), or a combination, was technically
feasible in all patients. Saccography during DPSI revealed a previously undetected type I endoleak in three patients.
Immediate DPSI success was achieved in 16 of 18 procedures (88.9%), with two complications. Glue incidentally
intravasated in the inferior vena cava, causing a clinically nonsignificant subsegmental pulmonary artery embolism in one
patient, and the temporary development of a type III endoleak, possibly from graft puncture, in another. During a median
follow-up of 39 months (interquartile range, 13-88 months) after DPSI, recurrent endoleaks were observed in nine
patients (50.0%), one type I endoleak due to graft migration, five type II endoleaks, and three EOUO. The occurrence of
a re-endoleak during follow-up was significantly associated with dual-antiplatelet medication (0% in patients without
re-endoleak vs 44.4% in patients with re-endoleak; P  .023) and with a nonsignificant trend for the use of aspirin alone
(33.3% in patients without re-endoleak vs 80% in patients with re-endoleak; P  .094). Re-endoleak occurred in 33.3%
of the patients without antiplatelet medication and in 100% of patients with dual-antiplatelet medication (P  .026).
Thrombin was used as the sole embolic agent during the initial DPSI in all patients with dual-antiplatelet therapy. No
other factor was significantly associated with re-endoleaks. Reintervention was deemed necessary in six patients within a
median of 10 months (interquartile range, 4-16 months) after DPSI, including six additional DPSI treatments in four
patients with type II re-endoleaks, cuff placements in one type I endoleak, and endograft relining in one EOUO.
Conclusions: This initial experience suggests that DPSI is feasible as a technique for endoleak treatment after EVAR.
However, complications and endoleak recurrence remain a concern. The role of antiplatelet therapy and different embolic
agents on long-term embolization success needs to be studied in more detail. ( J Vasc Surg 2012;56:965-72.)
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2Endovascular aneurysm repair (EVAR) has become the
first-line treatment option for patients with infrarenal ab-
dominal aortic aneurysms (AAA).1-3 Endoleaks are the
most common complication after EVAR and carry a poten-
tial risk of aneurysm enlargement and rupture. The re-
ported incidences of endoleaks vary widely, from 15% to
52%, and many patients subsequently require an endovas-
cular or surgical reintervention.4-6 Reinterventions for type
I and III endoleaks usually require endovascular placement
of aortic cuffs or graft extensions, or both. However, there
is continuing uncertainty regarding the management of
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http://dx.doi.org/10.1016/j.jvs.2012.03.269atients with type II endoleaks and endoleaks of undefined
rigin (EOUO). Several techniques have been described to
reat these endoleaks, including transarterial, transcaval,
nd translumbar approaches.7-10 The aim of this study was
o evaluate the feasibility and efficacy of direct percutane-
us sac injection (DPSI) for postoperative endoleak treat-
ent after EVAR.
ETHODS
Patient population. Between March 1994 and No-
ember 2011, EVAR of an infrarenal AAA was performed
n 986 patients at Baptist Cardiac & Vascular Institute
iami, and data were prospectively entered into an elec-
ronic database. Patients were routinely monitored at the
nstitution and follow-up included computed tomography
ngiography (CTA) before discharge or at 30 days, or at 6
nd 12 months postoperatively and annually thereafter.
he Social Security Death Index (http://ssdi.rootsweb.
om) was used to determine mortality as of November 15,
011, and if unknown, the patient’s primary physician was
ontacted to evaluate the cause of death.
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October 2012966 Uthoff et alMean follow-up was 63  45 months (range, 0-211
months) for the study population. Retrospective analysis of
the database was performed, and Fig 1 displays the study
flow. Endoleaks were defined according to the reporting
standards for EVAR.11,12 Type I and type III endoleaks
were treated by placement of an aortic cuff or endograft
extension, or both. Type II endoleaks and EOUO treat-
ment was considered if endoleaks were persistent for 12
months or if a sac enlargement of 5 mm between
follow-up imaging was observed, or both.
In general, an endovascular transarterial approach was
used for treatment of type II endoleaks. If the transarterial
approach was unsuccessful, subsequent DPSI for treatment
was considered. However, the treatment approach was at
the discretion of the operators, and DPSI was considered a
viable first-line treatment if, based on the preprocedure
CTA, the transarterial route was judged to be difficult; for
example, occluded hypogastric artery, occluded inferior
mesenteric artery (IMA), or tortuous access vessels. To
limit radiation and contrast exposure, no additional diag-
nostic angiograms were performed to plan the route of
intervention.
DPSI technique. Prior CT imaging was reviewed to
determine the site of the endoleak and the best approach
Fig 1. Retrospective analysis of 986 endovascular abdom
at a single institution. In total, 27 direct percutaneous sa
postoperative endoleaks were identified during a mean fofor the DPSI using anatomic landmarks. The patients were Blaced accordingly prone or supine on the angiography
able and a 21-gauge (0.83 mm)  15 cm Accustick
iagnostic needle (Boston Scientific, Natick, Mass) was
sed to puncture the aneurysm sac at the suspected en-
oleak site under fluoroscopic guidance. More recently,
dvanced imaging tools using cone-beam CT and XperCT
nd XperGuide real-time guidance (Philips Medical, Best,
he Netherlands) have been used for needle placement.
loody backflow indicated successful needle entry into the
neurysm sac and was confirmed by hemodynamic pressure
easurements upon entry into the aneurysm sac in most
ases. In patients with complex anatomy and at the discre-
ion of the primary operator, CT and ultrasound were also
sed to guide the puncture or confirm the needle position
n the aneurysm sac, or both. In addition, saccography was
erformed in most cases to verify the endoleak site and
ype.
An 0.018-inch nitinol guidewire was used to exchange
he needle for a 4F dilatator and a 20-cm 6F sheath to
nable deployment of Nester/Tornado embolization coils
CookMedical, Bloomington, Ind) or insertion of a micro-
atheter to direct embolization more precisely if an en-
oleak secondary to a lumbar or inferior mesenteric artery
as observed. However, thrombin (King Pharmaceuticals,
ortic aneurysm (EVAR) patients with EVAR performed
ction (DPSI) procedures in 21 patients for treatment of
-up of 63  45 months.inal a
c injeristol, Tenn), gelfoam (Pfizer Inc, New York, NY), or
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Volume 56, Number 4 Uthoff et al 967Trufill glue (Cordis Corp, Bridgewater, NJ), or a combina-
tion of these, occasionally were also injected under direct
imaging guidance into the sac via the introducer needle
only. The choice of embolic agent was at the discretion of
the operator. We have the most experience with thrombin,
and thus, it was used as a primary embolic agent, and in
general, coils were used to embolize inflow or outflow
vessels, or both, selectively whenever possible. The end
point for embolization was documented stable contrast
medium inside the aneurysm sac or a flat-lined hemody-
namic pressure waveform within the sac, or both.
DPSI success assessment. Imaging immediately after
the procedure, including unenhanced CT or conventional
angiography, or both, was performed in all patients under-
going DPSI to document the immediate success of DPSI.9
The evidence of stable contrast medium inside the aneu-
rysm sac or flat-lined hemodynamic pressure waveform
within the sac, or both, along with no evidence of an
immediate complication, was defined as an immediate suc-
cess of DPSI. Follow-up for all patients after discharge
consisted of clinical examination and CT scans at30 days,
6 months, 1 year, and annually thereafter. An experienced
interventional radiologist reviewed the images to identify
the presence, origin, and etiology of endoleaks. Clinical
success was defined as the absence of recurrent endoleak
during follow-up.
Statistical analysis. Demographic and clinical param-
eters are expressed as mean standard deviation or median
and interquartile range (IQR), as appropriate. The 2 test,
the unpaired t test, or the Mann-WhitneyU test were used,
as appropriate, for comparisons between groups. The level
of significance was set at a two-sided P .05 for all analyses.
Analyses were performed using SPSS 20 software (IBM
Corp, Armonk, NY).
RESULTS
An endoleak was detected in 270 of 986 patients
(27.4%), and in 131 of the 270 patients a reintervention for
endoleak treatment was performed, including more than
one intervention in 30.5%. Of these, 21 (16.0%) underwent
DPSI for treatment of type II endoleaks, in which 19 (84%)
were assumed to be secondary to lumbar arteries and two
were EOUO, and 12 (57%) were after failure of a previous
transarterial treatment attempt.
Baseline characteristics of the patients undergoing DPSI
are summarized in Table I. Patients were amedian age of 77.6
years and 90.5% were men. Patients had multiple comorbidi-
ties, with a high prevalence of chronic kidney disease grade of
3 (75%) and coronary artery disease (81%). All patients
had an American Society of Anesthesiologists classification of
3 or 4. Hypertension and smoking were the most prevalent
modifiable risk factors. Prescribedmedical therapy included
aspirin in 12 patients, dual-antiplatelet therapy (aspirin and
clopidogrel) in four, warfarin in eight, and aspirin and
warfarin in one.
The median interval between the initial EVAR proce-
dure and DPSI was 34 months (IQR, 14-62 months). Of
the 12DPSI procedures scheduled due to a persistent (12 eonths) type II endoleak, 11 were performed before 2004,
nd in 58% of these, a per-definition nonsignificant sac
able I. Patient characteristics before direct
ercutaneous sac injection (DPSI)
ariable
Median (IQR) or
No. (%)
(n  21)
ge, years 77.6 (71.2-83.6)
ale 19 (90.5)
ody mass index, kg/cm2 28.3 (24.9-31.2)
aseline
Hemoglobin, g/dL 13.8 (11.9-14.8)
Creatinine clearance, mL/mina 51.3 (33.6-58.2)
tage of chronic kidney disease
1: GFR 90 mL/mina 0 (0)
2: GFR 90-60 mL/mina 3 (14.3)
3: GFR 60-30 mL/mina 14 (66.7)
4: GFR 30-15 mL/mina 4 (19.0)
5: GFR 15 mL/mina 0 (0)
iabetes mellitus 2 (9.5)
yperlipidemia 13 (61.9)
ypertension 19 (90.5)
hronic obstructive pulmonary disease 10 (47.6)
istory of
Smoking 19 (90.5)
Cerebrovascular disease 3 (14.3)
Peripheral arterial occlusive disease 4 (19.0)
Coronary artery disease 17 (81)
nticoagulant/antiplatelet therapy 19 (90.5)
SA score
1 0 (0)
2 0 (0)
3 19 (90.5)
4 2 (9.5)
ype of stent graft
Ancureb 6 (28.6)
AneuRxc 3 (14.3)
Endurantc 1 (4.8)
Excluderd 4 (19.0)
Talentc 5 (23.8)
Zenithe 2 (9.5)
ndoleak reintervention 12 (57)
ime from EVAR to DPSI, days 1029 (407-1852)
ndication for DPSI
Aneurysm sac enlargement 5 mm 9 (42.9)
Persistent type II endoleak
12 months  sac enlargement 5 mm 7 (33.3)
12 months 5 (23.8)
Other 0 (0)
edian increase in sac diameter, mm 4 (	3 to 13)
neurysm sac diameter pre-DPSI, mm 63 (55-71)
ype of endoleak
IB (distal) 1 (4.8)
II 16 (76.2)
III 0 (0)
IV 0 (0)
Endoleak of unknown origin 2 (9.5)
SA, American Society of Anesthesiologists; EVAR, endovascular aortic
neurysm repair; GFR, glomerular filtration rate; IQR, interquartile range.
Calculated by Cockroft-Gault formula.
Guidant, Indianapolis, Ind.
Medtronic, Minneapolis, Minn.
W. L. Gore and Associates, Flagstaff, Ariz.
Cook Medical, Bloomington, Ind.nlargement of 2 to 5 mm was also observed.
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October 2012968 Uthoff et alDPSI procedure and short-term results. DPSI pro-
cedures were predominantly performed in an endovascular
suite (90.5%), and accordingly, fluoroscopy was used in
71.4% of cases as a guiding modality. Sac puncture was
achieved by CT guidance in four patients and by ultra-
sound guidance alone in two. Procedure-specific data are
summarized in Table II. DPSI was feasible in all patients.
Thrombin was used in 16 patients (76.2%), with ancillary
deployment/injection of coils (n  7), gelfoam (n  6),
or glue (n  3).
Two major complications during 21 DPSI were noted
(Table III). Owing to only partial thrombosis of the aneu-
rysmal sac after injection of 1300 units of thrombin from a
right lateral approach, a decision was made to use Trufill
glue. Approximately 1.5 mL of glue was injected with
subsequent complete thrombosis of the aneurysmal sac.
However, while withdrawing the catheter, incidental intra-
vasation of glue in the right lateral aspect of the inferior
vena cava was noted, subsequently causing a clinically non-
significant right lower subsegmental pulmonary artery em-
Table II. Procedure-specific data
Variablea
DPSI
(n  21)
Re-DPSI
(n  6)
Procedure room
Interventional radiology
suite 19 (90.5) 6 (100)
Computed tomography
suite 2 (9.5) 0 (0)
Operating room 0 (0) 0 (0)
Patient positioning
Prone 18 (85.7) 6 (100)
Supine 3 (14.3) 0 (0)
Procedure time, minutes 81 (46-136) 108 (78-120)
Fluoroscopy time, minutes 9.0 (4.4-19.6) 21 (10-41)
Contrast volume, mL 50 (21-84) 31 (25-75)
Type of anesthesia
Local 21 (100) 6 (100)
Regional 0 (0) 0 (0)
General 0 (0) 0 (0)
Approach used
Retroperitoneal 18 (85.7) 6 (100)
Anterior 3 (14.3) 0 (0)
Guiding imaging modality
Fluoroscopy 12 (57.1) 4 (66.7)
Computed tomography 4 (19.0) 1 (16.7)
Ultrasound imaging 2 (9.5) 0 (0)
Fluoroscopy  XperCTb 3 (14.3) 1 (16.7)
Agents used for
embolization
Thrombin 16 (76.2) 5 (83.3)
Dose, IU 1150 (850-2000) 775 (600-1000)
Coils (Nestor/Tornado)c 7 (33.3) 2 (33.3)
Number used 8 (4-15) 4,4
Glue 3 (14.3) 1 (16.7)
Gelfoam 6 (28.6) 0 (0)
DPSI, Direct percutaneous sac injection.
aCategoric data are shown as number (%) and continuous data as median
(interquartile range).
bPhilips Medical, Best, The Netherlands.
cCook Medical, Bloomington, Ind.bolism. In a second patient, a new type III endoleak of the uontralateral limb was identified at the end of a complex
PSI for type II endoleak treatment, likely due to a small
atrogenic graft perforation. At the time of the scheduled
eintervention 2 weeks later, the type III endoleak was not
etectable during several selective angiograms. Both pro-
edures with complications were guided by fluoroscopy
lone.
During DPSI with saccography, the presence of an
nsuspected type IA/B endoleak was diagnosed in three
atients, although previous CTAs suggested the presence
f a type II endoleak. Fig. 2 shows the saccography of a
atient with a type IA endoleak. Two patients were success-
ully treated by subsequent placement of an aortic cuff. One
atient refused any further treatment and died 61 months
ater. These patients were excluded from further analysis.
iven the two complications, immediate success was
chieved in 16 of 18 DPSI procedures (88.9%).
Midterm results after DPSI. Median follow-up after
PSI of the remaining 18 patients was 39 months (IQR,
3-88months). Recurrent endoleaks were observed in nine
atients (50.0%), with one type IA endoleak due to graft
igration, five type II endoleaks, and three EOUO. The
hange in sac diameter after DPSI was  0 mm (range,
-1.3 mm) in the patients without evidence of a recurrent
ndoleak and 3 mm (0 to 12 mm) in the patients with a
e-endoleak (P  .08).
Reintervention was deemed necessary in six patients
ithin amedian of 10months (IQR, 4-16months), includ-
ng the patient with the type IA endoleak, and five patients
ith type II endoleak/EOUO and 5 mm enlarging an-
urysm sac. No reintervention was deemed necessary in
hree patients without significant aneurysm sac enlarge-
ent. One of these patients died of pneumonia-related
espiratory failure 63 months after detection of a small type
Ia re-endoleak. Two patients are alive, at 118 months and
months, after diagnosis of a recurrent type II endoleak
nd an EOUO, respectively. Both patients are currently
able III. Complications during 27 direct percutaneous
ac injection (DPSI) procedures in 21 patients
omplication
DPSI
(n  21)
No. (%)
Re-DPSI
(n  6)
No. (%)
nitial
Bleeding 0 (0) 0 (0)
Organ perforation 0 (0) 0 (0)
Nerve injury 0 (0) 0 (0)
Graft perforation 1 (4.8) 0 (0)
Pulmonary embolism 1 (4.8) 0 (0)
Other 0 (0) 0 (0)
ate
Bleeding 0 (0) 0 (0)
Organ perforation 0 (0) 0 (0)
Nerve injury 0 (0) 0 (0)
Other 0 (0) 0 (0)nder close surveillance for sac enlargement.
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Volume 56, Number 4 Uthoff et al 969The clinical course of the six patients with reinterven-
tion is displayed in Fig 3. Patient 1, with a new type I
endoleak, was successfully treated by placement of an aortic
cuff. Patient 2, with an EOUO, was treated with endograft
relining. Conversion to open surgery was considered, but
owing to multiple comorbidities and the patient’s prefer-
ence, an endovascular approached was used. The sac
showed shrinkage during subsequent follow-up.
Another treatment with DPSI was performed in the
remaining four patients. In patient 3, DPSI for a recurrent
type II endoleak (a collateral network that opacifies an
accessory lower pole renal artery that was occluded at the
time of the initial EVAR) resulted in immediate success;
however, the patient was lost to follow-up and died of an
aorta-unrelated cause 19 months later. In patient 4, an
endovascular approach was first used for treatment of a type
IIA endoleak, but during both endovascular intervention
and subsequent DPSI, embolization of the culprit lumbar
artery failed. The patient is currently under close surveil-
lance.
Two DPSI reinterventions were performed in two pa-
tients. In patient 5, endoleak treatment using a combined
approach with transarterial coiling of an iliolumbar artery
and DPSI was successful (embolization of the iliolumbar
vessel was not possible during the first DPSI repeat proce-
dure); however, the patient died of urosepsis 8 months
later. Patient 6 presented with a slowly increasing aneurysm
sac, but no endoleak source could be detected. Thrombin
was administered into the aneurysm sac for an attempt at
thrombosis within the sac twice, and the sac size was stable
Fig 2. Saccography performed during a direct percutaneous sac
injection for an assumed type II endoleak demonstrated a type IA
endoleak (arrow).at subsequent CT follow-up. BIn summary, clinical midterm success, as defined above,
as achieved in nine of 18 patients (50%), and no aorta-
elated deaths were observed. The occurrence of a re-
ndoleak during follow-up was significantly associated with
ual-antiplatelet medication (aspirin and clopidogrel) (0%
n patients without re-endoleak vs 44.4% in patients with
e-endoleak; P  .023) and with a nonsignificant trend for
he use of aspirin alone (33.3% in patients without re-
ndoleak vs 80% in patients with re-endoleak; P  .094).
ne-third of the patients without antiplatelet medication
xperienced a re-endoleak, in contrast to all patients with
ual-antiplatelet medication (P  .026). Thrombin was
sed as sole embolic agent during the initial DPSI in all
atients with dual-antiplatelet therapy. No other factors,
ncluding previous endoleak intervention, aneurysm sac
ize, endoleak type, embolization material used, procedure
ime, or warfarin medication, were associated with the
ccurrence of subsequent repeat endoleaks or repeat inter-
entions.
Of note, no thrombin was used during DPSI in two
f the 18 patients. One patient with sac enlargement due
o a type II endoleak with multiple lumbar arteries was
reated by glue embolization alone, and a small recurrent
ndoleak was observed 22 months after the DPSI. How-
ver, no sac enlargement was observed during subse-
uent follow-up, and the patient died of pneumonia 85
onths after the initial DPSI. The other patient was
reated by placement of multiple coils within the sac by
PSI and concomitant transarterial coil embolization of
he IMA. No endoleak was observed in this patient
uring 104 months of follow-up. Both patients were on
herapy with aspirin alone.
ISCUSSION
This study reports our experience with DPSI for the
reatment of endoleaks in a large cohort of EVAR patients.
uring 27 DPSI procedures in 21 patients, we observed
ve major findings:
● DPSI was technically feasible in all cases.
● The rate of complications was low but not negligible
(7.4%).
● DPSI seemed to be an effective alternative method to
determine the type of endoleak.
● The recurrence of endoleaks during a median
follow-up of 39 months after DPSI was high (50%)
and reintervention deemed necessary in 33%.
● The occurrence of re-endoleaks during follow-up was
associated with (dual) antiplatelet therapy.
Endoleaks are the most common complication after
VAR, and the observed rate of endoleaks (27.4%) in our
VAR cohort was within the reported range of endoleak
ncidences (15% to 52%).4-6 Several case reports and small
ase series described (endovascular) techniques to treat
ndoleaks, including transarterial, transcaval, and translum-
ar approaches.7-10 In a comparison of transarterial vs
ranslumbar techniques for treatment of type II endoleaks,
aum et al13 reported a significantly higher treatment
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October 2012970 Uthoff et alsuccess with a translumbar approach. Only one of 13 pa-
tients (8%) was reported to have developed a new attach-
ment site endoleak during a median follow-up of 254 days,
compared with a 80% failure rate after transarterial embo-
lization.
We used a similar technique for DPSI, but unlike the
translumbar technique, our approach was not limited to
a “translumbar” access but also included ventral ap-
proaches to access the endoleak site when anatomically
appropriate. In fact, we observed a high initial technical
success rate with our approach. However, the assessment
of endoleak elimination by contrast stagnation during
saccography or nonenhanced CT, or both, in our study
might have overestimated the real success rate because
possibly not all endoleaks are connected to the stagnant
contrast.
The observed endoleak recurrence rate in our larger
cohort was significantly higher (50%) than previously
reported. A selection bias toward treatment of more
resistant endoleaks by performing DPSI only on en-
doleaks with an unsuitable transarterial approach, and
the significantly longer follow-up in our study of 39
months, are two explanations for the observed lower
effectiveness of DPSI in our cohort. Additional factors
may have contributed to this finding; for example,
thrombin was the predominant agent used in our cohort,
and coils were not used in all cases.
There are no prospective (randomized controlled)
data comparing different agents for embolization. In our
case series, univariate analysis did not reveal an associa-
tion between agents used and endoleak recurrence. Oth-
ers have successfully used thrombin to treat endoleaks;
for example, no endoleak recurrence was noted by Man-
Fig 3. Clinical course is shown of the six patients with
(DPSI) for type II endoleaks. The type of endoleak is disp
The numbers indicate the sac size. EOUO, Endoleak ofsueto et al9 using thrombin as a primary embolization ggent. Theoretically, permanent embolic agents like glue
r onyx (ethylene-vinyl alcohol copolymer) may be bet-
er; however, clinical experience with these agents is
imited, and serious adverse advents, including colonic
schemia and lumbar plexopathy,14 have been reported.
e also experienced nontargeted dissemination of the
iquid glue during catheter withdrawal, causing a pulmo-
ary embolism in one patient. Furthermore, these agents
re more expensive, and onyx can render subsequent
urveillance more difficult by causing artifacts on CT
cans; thus, these agents were only used occasionally at
ur center.
Nevala et al15 reported their experiences in 13 pa-
ients with type II endoleaks using DPSI with coils,
hrombin, gelatin, onyx, and glue. The reported clinical
uccess rate after DPSI was similar to our results (50%),
ncluding a type II endoleak 4 years after the first DPSI,
ith an even worse success rate (20%) for transarterial
mbolization. A very recent study by Sarac et al14 re-
orted the long-term follow-up of type II endoleak
mbolization. Similar to our findings, despite early tech-
ical success in treating type II endoleaks (using glue in
1% of embolizations), a high rate of sac growth
37.9%), secondary interventions (20%), and need for
pen repairs (8.4%) was observed after 5 years of follow-
p.14 Of note, an association of re-endoleaks with exclu-
ive coil embolization was reported in this study.
A high rate (72% of 42) of persistent or recurrent
ndoleak at the last follow-up imaging at 26  20
onths after percutaneous endovascular intervention for
ype II endoleaks was reported by Aziz et al.16 Interven-
ions, including 44 translumbar sac injections (mainly
ervention after initial direct percutaneous sac injection
on top of the arrows and the treatment approach below.
ned origin; TAE, transarterial embolization. †Death.reint
layedlue or coils, or both) and transcatheter embolizations of
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Volume 56, Number 4 Uthoff et al 971nine IMAs and seven lumbar/hypogastric arteries, did
not appear to alter the rate of sac growth in their study.16
These results highlight the unsatisfying (long-term)
effectiveness of current percutaneous treatment options
for (recurrent) endoleak embolization. Obviously, type
II endoleaks are more complex than previously thought.
Some have linked the treatment of type II endoleaks to
the endovascular treatment of vascular malformations,
with both the nidus and feeding arteries requiring treat-
ment.10,17 The sole treatment of the sac by direct sac
injection or exclusive transarterial embolization of in-
flow/outflow vessels seem to be inappropriate to achieve
long-term success, regardless of the embolic agent used.
In line with others,14 we now treat as many endoleak
sources as possible, resulting in a combined treatment of
the inflow, the outflow, and the aneurysm sac itself.
We currently have no absolute preference for a specific
embolic agent. A combination of DPSI and transarterial
embolization thus might be a reasonable approach to
treat type II endoleaks, but data are currently missing. A
novel sac-anchoring endoprosthesis designed to limit the
occurrence of endoleaks showed encouraging initial clin-
ical results and might also help to address the problem of
type II endoleaks in the future more effectively.18,19
The observation in our study that dual-antiplatelet
medication was associated with re-endoleaks after DPSI
warrants further investigation. All patients with dual-
antiplatelet therapy developed a re-endoleak after DPSI
with thrombin injection. Antiplatelet therapy suppresses
blood coagulation and was reported to prevent effective
thrombus organization in the aneurysm sac. Recently,
Aoki et al6 reported that patients with multiagent anti-
platelet therapy are at increased risk of a lack of aneurysm
shrinkage 6 months after EVAR, possibly due to a lack of
thrombus “hardening.” However, owing to the limited
number of patients in our study and a possible type II
error, no firm recommendations with regard to antiplate-
let therapy and the best embolic agent could be made.
Adequately powered prospective studies are needed to
validate our findings. Nevertheless, DPSI with thrombin
injection alone seems to be insufficient for durable en-
doleak treatment in patients with effective (dual) anti-
platelet therapy. Noteworthy, DPSI might have some
value to recognize previously occult type I and III en-
doleaks, as observed in our cohort in 14.3% of the
procedures and in 21% of the cases reported by Aziz
et al.16
CONCLUSIONS
Our initial experiences suggest that DPSI is feasible as a
bailout technique for (persistent) endoleak treatment after
EVAR. However, complications and endoleak recurrence
remain a concern, and we do not recommend it as a (sole)
first-line treatment option. The role of antiplatelet therapy
and different embolic agents on long-term embolization
success needs to be studied in more detail.
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